Pre-earnings options volume in Crispr Therapeutics is normal with calls leading puts 19:5. Implied volatility suggests the market is anticipating a move near 4.9%, or $2.49, after results are released. Median move over the past eight quarters is 2.3%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- CRISPR Therapeutics to Participate in Upcoming Investor Conferences
- Crispr Therapeutics price target lowered to $70 from $100 at JMP Securities
- CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference
- Crispr Therapeutics call volume above normal and directionally bullish
- Crispr Therapeutics initiated with a Buy at EF Hutton